2024
Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancer
2022
Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?
Zhao Y, Haroun R, Sahu S, Schernthaner R, Smolka S, Lin M, Hong K, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers 2022, 14: 3615. PMID: 35892874, PMCID: PMC9329887, DOI: 10.3390/cancers14153615.Peer-Reviewed Original ResearchOverall survivalSecond TACEHepatocellular carcinoma patientsFirst TACECarcinoma patientsTumor responseInitial transarterial chemoembolizationMedian overall survivalTransarterial chemoembolization sessionsKaplan-Meier methodLonger overall survivalLog-rank testChemoembolization sessionsConsecutive patientsTransarterial chemoembolizationSurvival outcomesHCC patientsTreatment responseTumor enhancementPatientsSurvival analysisTACEEuropean AssociationRespondersSignificant differencesResponse assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization
Adam LC, Savic LJ, Chapiro J, Letzen B, Lin M, Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Clinical Imaging 2022, 89: 112-119. PMID: 35777239, PMCID: PMC9470015, DOI: 10.1016/j.clinimag.2022.06.013.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionHepatic metastasesResponse assessment methodsPartial responseTransarterial chemoembolizationResponse assessmentTumor primaryStratification of responseRare primary tumorResponse Evaluation CriteriaRetrospective bicentric studyAssessment of responseQuantitative European AssociationLiver metastasesMajor complicationsBicentric studyPrimary tumorRare tumorEarly surrogateTreatment responseCT scanPatientsRECISTSolid tumorsOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
Frangakis C, Sohn JH, Bas A, Chapiro J, Schernthaner RE, Lin M, Hamilton JP, Pawlik TM, Hong K, Duran R. Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure. Frontiers In Oncology 2021, 11: 639235. PMID: 34804911, PMCID: PMC8602787, DOI: 10.3389/fonc.2021.639235.Peer-Reviewed Original ResearchPortal venous pressureChild-PughTransarterial chemoembolizationPlatelet countTumor burdenVenous pressureSpleen volumeHCC patientsEastern Cooperative Oncology Group performance statusEnd-stage liver disease (MELD) scorePortal hypertension-related complicationsNon-invasive surrogate markerBaseline spleen volumeBaseline tumor burdenRepeated Transarterial ChemoembolizationHigh tumor burdenHypertension-related complicationsLiver Disease scoreOutcomes of interestInstitutional review boardPost TACEPortal hypertensionMetastatic patientsPerformance statusBlood workComparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model
Doemel LA, Santana JG, Savic LJ, Gaupp FML, Borde T, Petukhova-Greenstein A, Kucukkaya AS, Schobert IT, Hamm CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology 2021, 32: 2437-2447. PMID: 34718844, PMCID: PMC9359419, DOI: 10.1007/s00330-021-08337-3.Peer-Reviewed Original ResearchConceptsDrug-eluting embolicsImmune cell infiltrationAntigen-presenting cellsBicarbonate infusionConventional TACEDEE-TACETransarterial chemotherapyCell infiltrationImmune cellsPeritumoral infiltrationT lymphocytesIntratumoral immune cell infiltrationTumor modelRabbit VX2 liver tumor modelImmunological tumor microenvironmentVX2 liver tumor modelIntra-arterial therapyIntra-arterial treatmentRabbit VX2 tumor modelLiver tumor modelTumor-bearing rabbitsVX2 tumor modelMann-Whitney U testIntratumoral presenceTransarterial chemoembolizationLipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinomaRole of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma
Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Scientific Reports 2021, 11: 9337. PMID: 33927226, PMCID: PMC8085245, DOI: 10.1038/s41598-021-88426-x.Peer-Reviewed Original ResearchConceptsTotal tumor volumeConventional transarterial chemoembolizationTumor diameterIntrahepatic cholangiocarcinomaOverall survivalTumor areaICC patientsTumor volumeHigh tumor burden groupTumor analysisOS of patientsHazard ratioTransarterial chemoembolizationTumor burdenBurden groupConventional chemoembolizationHTB groupRetrospective analysisPatientsSurvival curvesMultivariate analysisChemoembolizationCholangiocarcinomaETVBaseline imagesThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseMolecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment
Savic LJ, Schobert I, Peters D, Walsh JJ, Laage-Gaupp F, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment. Clinical Cancer Research 2020, 26: 428-438. PMID: 31582517, PMCID: PMC7244230, DOI: 10.1158/1078-0432.ccr-19-1702.Peer-Reviewed Original ResearchConceptsMR spectroscopic imagingLocoregional therapyLiver cancer microenvironmentConventional transarterial chemoembolizationNew Zealand white rabbitsTumor pHMost liver tumorsZealand white rabbitsMolecular imaging paradigmsPositive therapeutic outcomesTumor residualsTransarterial chemoembolizationTumor devascularizationHistopathologic markersViable tumorSurrogate biomarkerLiver tumorsLiver cancerTumor enhancementLiver parenchymaMetabolic markersMultiparametric MRITherapeutic outcomesHIF-1αVX2 tumors
2017
The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clinical Imaging 2017, 46: 1-7. PMID: 28668723, PMCID: PMC5720941, DOI: 10.1016/j.clinimag.2017.05.007.Peer-Reviewed Original ResearchConceptsEarly response assessmentTransarterial chemoembolizationImaging-based criteriaResponse assessmentHepatocellular carcinomaTumor response assessmentAnti-angiogenic therapyQuantitative European AssociationTherapy armOverall survivalLiver criteriaAntiangiogenic therapyTreatment groupsPatientsSimilar associationEuropean AssociationBevacizumabChemoembolizationCarcinomaTherapyAssociationAssessmentFollowCriteriaBaseline
2016
4:12 PMAbstract No. 77 Does lesion enhancement pattern correlate between baseline MR and follow-up CT in patients with hepatocellular carcinoma (HCC) treated using conventional transarterial chemoembolization (cTACE)? A quantitative, multi-modality analysis
Treilhard J, Smolka S, Manzano W, Chapiro J, Gebauer B, Geschwind J, Duncan J, Lin M. 4:12 PMAbstract No. 77 Does lesion enhancement pattern correlate between baseline MR and follow-up CT in patients with hepatocellular carcinoma (HCC) treated using conventional transarterial chemoembolization (cTACE)? A quantitative, multi-modality analysis. Journal Of Vascular And Interventional Radiology 2016, 27: s39. DOI: 10.1016/j.jvir.2015.12.110.Peer-Reviewed Original Research3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. European Radiology 2016, 26: 3243-3252. PMID: 26762942, PMCID: PMC4942412, DOI: 10.1007/s00330-015-4168-3.Peer-Reviewed Original ResearchConceptsHazard ratioOverall survivalTransarterial chemoembolizationBaseline MRIHepatocellular carcinomaTumor burdenDominant lesionTumor assessmentTumor volumeMultivariate cox proportional hazard ratiosCox proportional hazard ratiosCurrent radiological methodMethodsThis retrospective analysisProportional hazard ratiosBCLC staging systemKaplan-Meier plotsTumor diameterPatient survivalStaging systemHCC patientsMultiple lesionsLiver volumeRetrospective analysisLesion assessmentPatients
2015
Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. CardioVascular And Interventional Radiology 2015, 38: 1548-1556. PMID: 26001366, PMCID: PMC4651808, DOI: 10.1007/s00270-015-1129-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyContrast MediaEthiodized OilFemaleFollow-Up StudiesHumansImage EnhancementImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsLipiodol depositionConventional transarterial chemoembolizationTumor responseOverall tumor volumeTumor volumeCE-MRIHepatocellular carcinomaTransarterial chemoembolizationTumor necrosisContrast-enhanced magnetic resonance imagingNecrotic tumour volumeResponse Evaluation CriteriaT-testMagnetic resonance imagingStudent's t-testMethodsThis IRBTarget lesionsRetrospective analysisSolid tumorsResonance imagingSpearman rank-order correlationPatientsCone-beam CTCBCTChemoembolizationFeasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization.
Schernthaner RE, Chapiro J, Sahu S, Withagen P, Duran R, Sohn JH, Radaelli A, van der Bom IM, Geschwind JF, Lin M. Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization. Radiology 2015, 277: 833-41. PMID: 26000642, PMCID: PMC4654716, DOI: 10.1148/radiol.2015142821.Peer-Reviewed Original ResearchConceptsCone-beam CTTransarterial chemoembolizationLiver volumeRadiation exposureInstitutional review board-approved studyPeripheral hepatic tumorsSecondary liver cancerCT radiation exposureCone beam CT examinationsBoard-approved studyTumor detectabilityRadiation exposure reductionHepatic tumorsCT examinationsLiver cancerCT protocolPatientsCone beamMagnetic resonance imagesCT indicesC-arm rotatesCTTumorsExposure reductionRank testA new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization
Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization. European Radiology 2015, 25: 3255-3262. PMID: 25956933, PMCID: PMC4595540, DOI: 10.1007/s00330-015-3717-0.Peer-Reviewed Original ResearchConceptsDose area productDigital subtraction angiographyTransarterial chemoembolizationCone-beam CTRadiation exposureLiver cancerDSA image qualityCumulative dose area productSecondary liver cancerLiver cancer patientsTwo-arm trialSignificant differencesResultsBoth cohortsDiagnostic image qualityPatient characteristicsConsecutive patientsTumor burdenTACE proceduresCancer patientsSubtraction angiographyPatientsHIPAA compliantDigital fluoroscopyProcedure courseIndependent readersHow I Do It: Cone-Beam CT during Transarterial Chemoembolization for Liver Cancer
Tacher V, Radaelli A, Lin M, Geschwind JF. How I Do It: Cone-Beam CT during Transarterial Chemoembolization for Liver Cancer. Radiology 2015, 274: 320-334. PMID: 25625741, PMCID: PMC4314294, DOI: 10.1148/radiol.14131925.Peer-Reviewed Original ResearchConceptsTransarterial chemoembolizationLiver cancerContrast material injection protocolsTime of procedureTwo-dimensional angiographyClinical evidenceTreatment successLiver tumorsMicrocatheter placementInterventional radiologyInterventional proceduresCBCT technologyDiagnostic imagingCone beamInjection protocolCBCT techniqueCBCT imagingCone-beam CTTumorsRoutine utilizationChemoembolizationCBCT imagesC-armCancerCBCT1:27 PM, Abstract No. 119 Can whole liver enhancement patterns predict survival in patients with extensive neuroendocrine liver metastases treated with transarterial chemoembolization?
Sahu S, Duran R, Schernthaner R, Sohn J, Chapiro J, Lin M, Geschwind J. 1:27 PM, Abstract No. 119 Can whole liver enhancement patterns predict survival in patients with extensive neuroendocrine liver metastases treated with transarterial chemoembolization? Journal Of Vascular And Interventional Radiology 2015, 26: s58. DOI: 10.1016/j.jvir.2014.12.160.Peer-Reviewed Original ResearchNeuroendocrine liver metastasesLiver metastasesTransarterial chemoembolizationEnhancement patternChemoembolizationPatientsMetastasisEarly survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver
Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, Savic LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. European Radiology 2015, 25: 1993-2003. PMID: 25636420, PMCID: PMC4458393, DOI: 10.1007/s00330-015-3595-5.Peer-Reviewed Original ResearchConceptsIntra-arterial therapyColorectal liver metastasesTransarterial chemoembolizationPatient survivalHazard ratioLiver metastasesOverall survivalResponse assessmentVolumetric tumour response assessmentCox proportional hazard ratiosMethodsThis retrospective analysisProportional hazard ratiosKaplan-Meier analysisColorectal cancer metastasisTumor response assessmentTumor analysisEarly survival predictionQuantitative MRI assessmentMRI assessmentTumor responseLesion volumeRetrospective analysisMultivariate analysisPatientsPredictive role